BACKGROUND: Omega-3 fatty acid supplements have been reported to inhibit exercise-induced bronchoconstriction (EIB). It has not been determined whether omega-3 supplements inhibit airway sensitivity to inhaled mannitol, a test for bronchial hyperresponsiveness (BHR) and model for EIB in people with mild to moderate asthma.
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Dietary supplementation using omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) plays an uncertain role in the management of asthma, which has led to calls for more prospective studies to investigate whether there are any benefi ts from an omega-3-enriched diet in asthma. 1 Results have not been consistent when assessing high doses of dietary omega-3s on bronchial hyperresponsiveness (BHR), a key feature of asthma. Early studies administering omega-3s daily over 10 weeks demonstrated no attenuation of exercise-induced bronchoconstriction (EIB) 2 while causing a small decrease of the late airway response to inhaled allergen. 3 More recently, 3 weeks of omega-3s were reported to inhibit mild airway responses to exercise and eucapnic voluntary hyperventilation (EVH) in both elite athletes and symptomatic subjects with asthma. [4] [5] [6] Th is was observed in association with reductions in markers of airway infl ammation, such as reduced cytokine levels, reduced excretion of the urinary eicosanoids 11 b -prostaglandin F2 a (11 b -PGF 2 a ) and leukotriene E4 (LTE 4 ), and decreased sputum eosinophil counts, suggesting that the benefi ts of an omega-3-enriched diet on EIB was through antiinfl ammatory mechanisms.
Inhaled mannitol as a test for BHR has been demonstrated as a useful model for EIB, 7 and all pharmacotherapies eff ective at inhibiting EIB inhibit BHR to mannitol. [8] [9] [10] [11] Mannitol causes bronchoconstriction through an increase in the osmolarity of the airway surface fl uid, leading to mediator release from mast cells similar to the proposed mechanism for EIB. 12 Evidence for mediator release to mannitol is an increase in urinary eicosanoids 11 b -PGF 2 a and LTE 4 following a mannitol challenge 11 similar to what has been observed with exercise and EVH. 13, 14 BHR to mannitol identifi es EIB in elite athletes 15 and predicts the severity of EIB in people with asthma. 7 Considering these similarities, we evaluated whether dietary supplementation with omega-3 fatty acids could inhibit BHR to inhaled mannitol to assess the effi cacy of omega-3s in people with mild to moderate BHR. We assessed the eff ect of 3 weeks of dietary omega-3s on BHR to mannitol, sputum eosinophil counts, spirometry, and asthma symptoms in subjects with clinically defi ned steroid-naive asthma as well as in those using regular inhaled corticosteroids (ICSs). Urine and serum were collected during the study to determine the biochemical eff ects of the omega-3 supplementation on mast cell mediators derived from fatty acids.
Materials and Methods

Study Design
The study used a randomized, double-blind, placebo-controlled, and crossover trial design. Subjects attended the laboratory in the morning on four occasions occurring before and after two 3-week treatment periods. People taking ICSs were required to attend an extra initial visit 2 weeks prior to the commencement of the trial in order to perform a mannitol challenge to document that their airway sensitivity in the Part of this article has been presented in abstract form (Brannan JD 10 .1378/chest.14-1214 presence of ICS was reproducible over the run-in period and that their asthma was clinically stable.
Each visit comprised self-administered questionnaires (Asthma Control Questionnaire and Asthma Quality of Life Questionnaire); taking blood to assess fasting blood triglyceride, omega-3, and omega-6 fatty acid levels; obtaining a urine sample to assess urinary eicosanoid counts; assessing baseline lung function using spirometry; and performing a mannitol challenge followed by sputum induction. More details are provided in e-Appendix 1 . Upon meeting entry criteria, subjects were randomized to a 3-week supply of a daily dose of 10 capsules of either a matched placebo containing a blend of omega-6 and omega-9 or a ratio of omega-3 fatty acids comprising 400 mg EPA and 200 mg DHA (40/20EE capsules; Ocean Nutrition Canada). Th is equated to a daily dose of 4.0 g EPA and 2.0 g DHA. Each treatment period was separated by a 3-week washout. More details are provided in e- Figure 1 .
The protocol was approved by the ethics review board of St. Joseph's Healthcare, Hamilton, Ontario, Canada (R.P.#06-2750), and Health Canada (Approval No. 120532). All subjects gave written informed consent.
Subjects
Nonsmoking subjects with clinically diagnosed asthma and current asthma symptoms with an FEV 1 . 70% predicted were entered into the trial ( Fig 1 , Table 1 ). Short-acting b 2 -agonists were withheld for 8 h and long-acting b 2 -agonists for 48 h, and no ICSs were taken on the morning of the study. Antihistamines and leukotriene antagonists were not permitted throughout the whole study period. No caff eine-containing food or drink and no vigorous exercise were permitted on the study day prior to the study visit. Subjects were asked to abstain from fi sh meals or other signifi cant sources of omega-3s for at least 2 weeks prior to the study and throughout the study. 
Biochemical Measurements
Serum triacylglyceride levels and the fatty acid composition of the serum phospholipids were analyzed for triglycerides as well as omega-3 and omega-6 fatty acids. Th e eff ects of the dietary intervention on eicosanoid levels of 11 b -PGF 2 a and LTE 4 in urine were assessed by enzyme immunoassay, 11, 14 and an ultraperformance liquid chromatographytandem mass spectrometry platform 16 that measures . 90 diff erent lipid mediators. More details are provided in e-Appendix 1 .
Statistics
Th e primary outcome was the airway sensitivity to a provoking dose of mannitol (mg) to cause a 15% fall in FEV 1 (PD 15 ). Secondary outcomes were sputum eosinophil counts, baseline FEV 1 , and asthma symptoms scores. Spearman rank correlation was performed on nonnormally distributed data. For comparisons between groups, the Student t test was used for paired measurements, with P , .05 considered signifi cant. A sample size for each treatment group for PD 15 was based on a prior study demonstrating a clinically signifi cant improvement in association with decreased airway sensitivity to inhaled mannitol using ICS. 17 When raw data for PD 15 values were log2 converted, this study demonstrated a 1.9 doubling dose shift in the presence of ICS and a withinsubject SD of 0.7, yielding a sample size of four subjects at 80% power and a significance of .05. When calculating a minimal important diff erence of 1 doubling dose, assuming the same within-subject SD, this yielded a sample size of seven at 80% power and a significance of .05. Th e rate of spontaneous recovery of lung function following the challenge was calculated as an area under the % fall in FEV 1 vs time curve.
Results
Omega-3 fatty acid supplements were not eff ective at attenuating BHR to mannitol. The geometric mean PD 15 was 88 mg (95% CI, 56-139 mg) after placebo treatment and 78 mg (95% CI, 51-119 mg) after omega-3 fatty acid supplements ( P 5 .5). Th is represented a doubling dose shift in favor of placebo of 2 0.25 (SD, 1.1) and less than the minimal important diff erence of 1 doubling dose. Although the airway sensitivity to mannitol was in the moderate range for most subjects (PD 15 , 155 mg), those taking b 2 -agonists as needed were more sensitive to mannitol than those taking ICSs ( P 5 .03) ( Table 2 ). However, no diff erences were observed based on subjects' daily treatment ( Fig 2 , Table 2 , e- Fig 2) . In addition, there were no diff erences in the spontaneous recovery from mannitol between the omega-3 supplement and placebo groups. However, a subgroup analysis found those taking ICS had a slower recovery while on omega-3 supplements compared with placebo, and recovery time for the whole group was longer in the presence of omega-3 supplements compared with baseline ( Table 2 , e-Fig 3 ) .
The majority of subjects who could produce an adequate sputum sample had evidence of eosinophils ( . 2%) ( Table 1 ) , and there was a signifi cant relationship between the percentage of eosinophils and mannitol PD 15 ( r s 5 0.53, P 5 .047, n 5 14). However, in subjects who provided suitable sputum samples at the end of each treatment period (n 5 11), there were no diff erences in eosinophil counts following omega-3 supplementation (8.4% Ϯ 8.2%) compared with placebo (7.8% Ϯ 11.8%) ( Fig 3 ) .
Th ere were no signifi cant improvements in either lung function (baseline FEV 1 ) or asthma symptoms with the omega-3 supplements, with no changes in asthma control or asthma quality of life scores ( Table 2 ) . However, there was a 27% reduction in fasting blood triglyceride levels in subjects taking the omega-3 supplements compared with those taking placebo ( P , .001) as well as evidence of raised EPA and DHA serum levels in the presence of the omega-3 supplements compared with placebo ( P , .001) ( Figs 4 , 5 ) . This finding indicated biologic activity of the omega-3 supplements and that subjects were adherent to the dietary supplementation.
As further evidence of the eff ectiveness of the intervention, serum levels (mean Ϯ SEM) of the omega-3 fatty acid EPA-derived metabolites 12-hydroxyeicosapentaenoic acid (HEPE) and 15-HEPE increased significantly following omega-3 supplementation (0.6 Ϯ 0.1 pM vs 6.9 Ϯ 2.6 pM, P 5 .022) compared with placebo (0.1 Ϯ 0.02 pM vs 0.6 Ϯ 0.1 pM, P 5 .000024). Measurement of the analogous omega-6 fatty acid arachidonic acidderived metabolites 12-and 15-hydroxyeicosatetraenoic acid showed no changes (11 Ϯ 2 pM vs 17 Ϯ 5 pM and 1.3 Ϯ 0.1 pM vs 1.3 Ϯ 0.1 pM, respectively). Th e measurements of urinary levels (ng/mmol creatinine) of LTE 4 and the prostaglandin D2 (PGD 2 ) metabolite 11 b -PGF 2 a revealed no diff erences between the two treatments ( Table 2 ) ; thus, further characterization of the eff ect of omega-3 supplements on lipid mediator profi les using ultra-performance lipid chromatographytandem mass spectrometry was performed in a subset of subjects (n 5 5). No changes were found in the urinary excretion of any of the key metabolites of the primary prostaglandins or LTE 4 . However, there was a decrease in urinary prostaglandin E2 (PGE 2 ) by omega-3 supplements compared with placebo (29 Ϯ 19 units vs 141 Ϯ 52 units, respectively; P 5 .048). A decrease was also observed for 8,12-iso-iPF 2 a -VI aft er omega-3 supplementation compared with placebo (581 Ϯ 103 units vs 730 Ϯ 129 units, respectively; P 5 .0117). Th e levels of all lipid mediators measured in the urine are provided in e- Table 1 .
A post hoc power calculation of sample size using the data for PD 15 obtained in this study showed that the total sample size of 23 was of suffi cient power for assessing a minimal important diff erence of one doubling dose. Th e within-subject SD for a comparison of PD 15 values at the beginning of each treatment period before any treatment was administered and following washout (each separated by 6 weeks), was 1.2. Th e SD for the PD 15 values in the presence of the placebo and omega-3 fatty acid treatments (each also separated by 6 weeks) was 1.1. Th is yielded a sample size of 13 and 12 subjects, 
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respectively, at a power of 80% and a significance of 0.05. Individual data for PD 15 can be found in e- Table 2 . The doubling dose difference comparing the PD 15 values at the commencement of each treatment period was 0.25.
Discussion
Th is study demonstrates that a high daily dose of an omega-3 fatty acid supplement has no eff ect on either BHR to mannitol or sputum eosinophil percentage in subjects with mild to moderate asthma in association with no changes in asthma symptom control. Th e lack of eff ect was seen irrespective of whether the subjects had baseline treatment with as-needed b 2 -agonists or were maintained on ICS. Neither did the omega-3 fatty acid supplementation change the resting levels of key arachidonic acid-derived mediators of mast cell responses, such as the cysteinyl leukotrienes and prostaglandin D2. However, we did see an increase in the serum levels of the omega-3 fatty acid-derived products 12-and 15-HEPE aft er the active supplementation in association with the expected lowering of serum triglyceride levels, which together provide fi rm evidence that the subjects were adherent to the treatment.
Th e fi ndings are consistent with the initial observation that omega-3 fatty acids had no effect on EIB 2 but contradictory to other studies where similar doses of omega-3 supplements over the same treatment duration of 3 weeks were found to inhibit EIB 4,5 and EVH. 6, 18 The most obvious diff erence is that we used inhaled mannitol, a bronchial provocation challenge that has been derived from the understanding of the eff ects of dry air hyperpnea-induced BHR, which is a well-established alternative challenge stimulus to study EIB. There is strong evidence that the airway response to mannitol closely mimics central components of EIB, such as the activation of mast cells and eosinophils, resulting in the release of bronchoconstrictive mediators. 7, [9] [10] [11] [12] [13] 19, 20 However, the diff erences may lie in the intensity of the stimulus to the airways. Th e studies showing benefi t performed the exercise challenge until volitional exhaustion, which is a test that has a known low sensitivity to identifying EIB and which may induce milder airway responses in those with EIB. 4, 5 In both exercise and EVH studies by Mickleborough and colleagues, 4, 5 no data were provided in relation to the intensity or reproducibility of the exercise and ventilatory stimulus administered or whether this achieved the minimum requirements for each protocol to induce EIB.
Moreover, the current findings are consistent with earlier studies demonstrating that a 10-week treatment period with omega-3 supplements does not attenuate EIB using the standardized 8-min exercise protocol . 2 Th e authors assessed airway resistance (specifi c airway conductance) and not FEV 1 as a measure of airflow limitation. Th e same investigators, however, did demonstrate a small effect of omega-3s on the late airway response to allergen. 3 Interestingly, in a treatment study, the same group also found that omega-3 supplements changed the profi le of blood fatty acids and lipid mediator biosynthesis in circulating leukocytes but did not improve the clinical course of rhinitis or asthma. 21 In contrast to Mickleborough and colleagues, 4,5 we did not fi nd any signifi cant reductions in resting levels of infl ammatory markers, such as sputum eosinophils or the urinary metabolites of PGD 2 and LTE 4 with omega-3 fatty acids. Th e present fi ndings are consistent with studies in mice showing no eff ect of a 6-week treatment with EPA and DHA (using a similar equivalent dose) on suppressing ovalbumin-augmented eosinophils in an asthma mouse model, with evidence that DHA alone augments eosinophilia. 22 However, it was also shown in mice that both EPA and DHA can suppress PGE 2 in BAL. We also observed signifi cant reductions in PGE 2 excretion (its source likely from the kidney), which suggests that omega-3 fatty acids can modify prostaglandin metabolism. PGE 2 in the airway is believed to have a beneficial effect as an endogenous bronchodilator, providing bronchoprotection aft er exercise. 23 We did not notice any detrimental eff ect of the omega-3 supplements other than a small, but statistically signifi cant prolonged recovery from bronchoconstriction to mannitol in the presence of the omega-3 treatment; however, the clinical relevance of this is unclear. Slower recovery from mannitol challenge does suggest a direct role of leukotrienes. 10, 19 One study in humans has demonstrated worsening of daily peak fl ow and increased b 2 -agonist use with longer treatment of a daily dose of 3 g omega-3 fatty acids over 6 weeks in subjects with asthma and aspirin sensitivity. 24 Th e presumed mechanism for explaining the possible benefi cial eff ects of omega-3 fatty acids on infl ammatory pathways is through diversion of the production of bronchoconstricting prostaglandins and leukotrienes from the omega-6 substrate arachidonic acid to mediators biosynthesized from the alternative omega-3 substrates. Th is assumes that these alternative metabolites have weaker eff ects on the airway smooth muscle and infl ammatory eff ector cells. 4, 25 However, it has been shown that the 5-series leukotrienes derived from omega-3 fatty acids have the same bronchoconstrictive potency as the 4-series leukotrienes derived from arachidonic acid. 26 In addition, the generation of the 3-series prostaglandins with omega-3 supplements may not provide any benefi ts on airway infl ammation and BHR in an animal model. 22 Considering this, it may be that omega-3 supplements, even in high doses, fail to substantially alter the substrate fl ow in the tissue-residing cells, whereas in the blood, signifi cant concentrations exist to divert metabolism. It is well established that omega-3 fatty acids can eff ectively decrease serum triglyceride levels, as we observed in this study. Th us, omega-3 supplements may be eff ective in altering plasma fatty acid composition; function of blood cells; and metabolism in other cells exposed to high levels of circulating omega-3 fatty acids, such as vascular endothelium and renal tubular cells. Th is is supported by the current fi nding that the intervention caused a decrease in urinary PGE 2 , which is known to be derived directly from the kidney. 27 We suggest that it may be more diffi cult to change the metabolic profi le of cells within tissues, such as that of the airway mast cell, where there is most likely still sufficient arachidonic acid available as the preferred substrate for the activation-induced biosynthesis of cysteinyl leukotrienes and PGD 2 . During stimulation, arachidonic acid is liberated mainly by group 4 phospholipase A2 (or cytosolic phospholipase A2). This enzyme has preference for phospholipids with arachidonic acid, which may explain why in acute processes, displacing arachidonic acid with omega-3s is not eff ective to shield the production of arachidonic acid-derived eicosanoids. 28 Th e study was adequately powered for the primary outcome, and this was supported with the post hoc calculations. We powered the study expecting a clinically important difference based on the existing studies showing a 64% protection in the percent fall in FEV 1 aft er exercise in subjects with asthma taking omega-3 fatty acids 5 and considering this inhibition to be similar to what has been observed using ICS on both exercise and mannitol in subjects with asthma. 17, 29 Independent of ICS therapy, a patient with asthma who has a PD 15 will demonstrate considerable room for improvement in PD 15 in the presence of improved ICS treatment (higher dose or improvement in adherence) 17, 30 and acute therapy using cromolyn drugs and b 2 -agonists. 11 A post hoc sample size analysis demonstrated that the individual treatment groups based on the presence of ICS therapy or b 2 -agonists as needed were either adequately powered or slightly underpowered, suggesting that a minimum of 12 to 13 subjects are required when using inhaled mannitol in a study assessing an intervention and looking for a minimal important difference of 1 doubling dose. Considering the 0.25 doubling dose diff erence in favor of placebo, this possible slight underpowering for each treatment group is likely of no signifi cance.
In conclusion, a diet enriched with omega-3 fatty acids over a 3-week treatment period had no clinical benefi ts in either steroid-treated or steroid-naive subjects with asthma, as confi rmed by no observed improvements on the two key features of asthma: BHR and airway infl ammation. Furthermore, there was no evidence of signifi cant changes in resting eicosanoid metabolism caused by the omega-3 supplements, even though expected changes in serum omega-3 fatty acid metabolism and decreases in serum triglyceride levels were seen. Th ese data suggest that in people with asthma, high daily doses of omega-3 fatty acids from fi sh oils are not an alternative or additive treatment strategy for asthma. Further studies need to elucidate whether the degree of the stimulus to elicit EIB is a determining factor on the protective eff ect of omega-3 fatty acids and whether the same effect is observed following longer-term therapy. Considering this, the fi ndings have general ramifi cations, indicating that distinct manipulation of tightly controlled biologic responses in tissues by dietary intervention of omega-3 fatty acids is diffi cult.
